Innovative approaches to support smoking cessation for individuals with mental illness and co-occurring substance use disorders

Expert Review of Respiratory Medicine

Volumn 11, Issue 10, 2017, Pages 841-850

  Das, Smita ^a   Prochaska, Judith J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP1A2; dual diagnosis; e cigarette; mental illness; nicotine; nicotine replacement therapy; quit line; smoking; substance use disorders; Tobacco

Indexed keywords

AMFEBUTAMONE; BASE; NICOTINE; NICOTINE PATCH; VARENICLINE; CYP1A2 PROTEIN, HUMAN; CYTOCHROME P450 1A2; NICOTINE GUM; NICOTINIC AGENT; PSYCHOTROPIC AGENT;

ADDICTION; BEHAVIOR THERAPY; DRUG DEPENDENCE; ELECTRONIC CIGARETTE; GENETIC SCREENING; HARM REDUCTION; HUMAN; MENTAL DISEASE; MENTAL HEALTH; MENTAL PATIENT; PASSIVE SMOKING; PREVALENCE; PSYCHOSOCIAL CARE; REVIEW; SMOKING BAN; SMOKING CESSATION; SUICIDAL BEHAVIOR; TOBACCO USE; COGNITIVE THERAPY; GENOME-WIDE ASSOCIATION STUDY; HOTLINE; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGY; SMOKING; SUICIDAL IDEATION; WITHDRAWAL SYNDROME;

COGNITIVE THERAPY; CYTOCHROME P-450 CYP1A2; ELECTRONIC NICOTINE DELIVERY SYSTEMS; GENOME-WIDE ASSOCIATION STUDY; HOTLINES; HUMANS; MENTAL DISORDERS; NICOTINIC AGONISTS; PSYCHOTROPIC DRUGS; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; SUICIDAL IDEATION; TOBACCO SMOKE POLLUTION; TOBACCO USE CESSATION PRODUCTS;

EID: 85029535341     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2017.1361823     Document Type: Review

References (114)

1. Grant BF, Hasin DS, Chou SP, et al. Nicotine dependence and psychiatric disorders in the United States:results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61(11):1107–1115.
2. Diaz FJ, Velásquez DM, Susce MT, et al. The association between schizophrenia and smoking:unexplained by either the illness or the prodromal period. Schizophr Res. 2008;104(1):214–219.
3. Diaz FJ, James D, Botts S, et al. Tobacco smoking behaviors in bipolar disorder:a comparison of the general population, schizophrenia, and major depression. Bipolar Disorders. 2009;11(2):154–165.
4. Kleber HD, Anton RF, Jr, George TP, et al. Treatment of patients with substance use disorders. In:American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders:compendium 2006. Arlington, Virginia:American Psychiatric Association. 2006. p. 291.
5. Parks J, Jewell P, Maile Burke M., Technical report on smoking policy and treatment in state operated psychiatric facilities. Editors:Parks J, and Jewell P., In:National Association of State Mental Health Program Directors. Alexandria (VA):Medical Directors Council. 2006.
6. Fu SS, McFall M, Saxon AJ, et al. Post-traumatic stress disorder and smoking:a systematic review. Nicotine Tob Res. 2007;9(11):1071–1084.
7. Klungsøyr O, Nygård JF, Sørensen T, et al. Cigarette smoking and incidence of first depressive episode:an 11-year, population-based follow-up study. Am J Epidemiol. 2006;163(5):421–432.
8. Eriksen M, Mackay J, Schluger N, et al. The tobacco atlas. 5th ed. revised, expanded and updated. Atlanta (GA):American Cancer Society; 2015.
9. McClave AK, McKnight-Eily LR, Davis SP, et al. Smoking characteristics of adults with selected lifetime mental illnesses:results from the 2007 National Health Interview Survey. Am J Public Health. 2010;100(12):2464–2472.
10. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness:a population-based prevalence study. JAMA. 2000;284(20):2606–2610.
11. Bowden JA, Miller CL, Hiller JE., Smoking and mental illness:a population study in South Australia. Aust NZ J Psychiatry. 2011;45(4):325–331.
12. Sung H-Y, Prochaska JJ, Ong MK, et al. Cigarette smoking and serious psychological distress:a population-based study of California adults. Nicotine Tob Res. 2011;13(12):1183–1192.
13. Gierisch JM, Bastian LA, Calhoun PS, et al. Smoking cessation interventions for patients with depression:a systematic review and meta-analysis. J Gen Intern Med. 2012;27(3):351–360.
14. Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol. 2004;72(6):1144–1156.
15. Schroeder SA, Morris CD. Confronting a neglected epidemic:tobacco cessation for persons with mental illnesses and substance abuse problems. Annu Rev Public Health. 2010;31:297–314.
16. US Department of Health Human Services. The health consequences of smoking—50 years of progress:a report of the Surgeon General. Atlanta (GA):US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014. p. 17.
17. Prochaska JJ, Gill P, Hall SM. Treatment of tobacco use in an inpatient psychiatric setting. Psychiatr Serv. 2004;55(11):1265–1270.
18. Oquendo MA, Galfalvy H, Russo S, et al. Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am J Psychiatry. 2004;161(8):1433–1441.
19. Breslau N, Schultz LR, Johnson EO, et al. Smoking and the risk of suicidal behavior:a prospective study of a community sample. Arch Gen Psychiatry. 2005;62(3):328–334.
20. Balbuena L, Tempier R. Independent association of chronic smoking and abstinence with suicide. Psychiatric Services. 2015;66(2):186–192.
21. Clarke DE, Eaton WW, Petronis KR, et al. Increased risk of suicidal ideation in smokers and former smokers compared to never smokers:evidence from the Baltimore ECA follow-up study. Suicide Life Threat Behav. 2010;40(4):307–318.
22. Steinberg ML, Williams JM, Ziedonis DM. Financial implications of cigarette smoking among individuals with schizophrenia. Tobacco Control. 2004;13(2):206–206.
23. Montoya ID, Herbeck DM, Svikis DS, et al. Identification and treatment of patients with nicotine problems in routine clinical psychiatry practice. Am J Addict. 2005;14(5):441–454.
24. Stuber J, Galea S, Link BG. Smoking and the emergence of a stigmatized social status. Soc Sci Med. 2008;67(3):420–430.
25. Prochaska JJ, Fletcher L, Hall SE, et al. Return to smoking following a smoke-free psychiatric hospitalization. Am J Addict. 2006;15(1):15–22.
26. Farley SM, Waddell EN, Coady MH, et al. Correlates of smoke-free housing policies and interest in implementing policies among multiunit housing owners in New York City. J Urban Health. 2015;92(2):291–303.
27. Prochaska JJ, Michalek AK, Brown-Johnson C, et al. Likelihood of unemployed smokers vs nonsmokers attaining reemployment in a one-year observational study. JAMA Intern Med. 2016;176(5):662–670.
28. Bandiera FC, Arheart KL, Caban-Martinez AJ, et al. Secondhand smoke exposure and depressive symptoms. Psychosom Med. 2010;72(1):68.
29. Bandiera FC, Richardson AK, Lee DJ, et al. Secondhand smoke exposure and mental health among children and adolescents. Arch Pediatr Adolesc Med. 2011;165(4):332–338.
30. Okoli CT, Khara M. Correlates of secondhand tobacco smoke exposure among individuals with a history of substance use and/or psychiatric disorders participating in a tobacco treatment program in Vancouver, Canada. Community Ment Health J. 2014;50(6):729–736.
31. Acquavita SP, McClure EA, Hargraves D, et al. Environmental tobacco smoke exposure among smokers and non-smokers receiving outpatient substance abuse treatment. Addict Behav. 2014;39(12):1718–1722.
32. Brown-Johnson CG, Sanders-Jackson A, Prochaska JJ. Online comments on smoking bans in psychiatric hospitals units. J Dual Diagn. 2014;10(4):204–211.
33. Cohen B, McGinnis S, Salsberg E. Physician behavior and practice patterns related to smoking cessation. Washington (DC):Association of American Medical Colleges; 2007.
34. Lawn S, Pols R. Smoking bans in psychiatric inpatient settings? A review of the research. Aust NZ J Psychiatry. 2005;39(10):866–885.
35. Prochaska JJ, Hall SM, Bero LA. Tobacco use among individuals with schizophrenia:what role has the tobacco industry played? Schizophrenia Bulletin. 2008;34(3):555–567.
36. Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27(4):380–386.
37. Prochaska JJ, Hall SE, Delucchi K, et al. Efficacy of initiating tobacco dependence treatment in inpatient psychiatry:a randomized controlled trial. Am J Public Health. 2014;104(8):1557–1565.• Randomized controlled trial of a multicomponent tobacco treatment intervention initiated during a smoke-free psychiatric hospitalization. Findings indicated significant treatment effects on tobacco abstinence out to 18-months follow-up and a lower likelihood of psychiatric re-hospitalization.
38. Das S, Hickman NJ, Prochaska JJ., Treating Smoking in Adults With Co-occurring Acute Psychiatric and Addictive Disorders. Journal of Addiction Medicine 2017;11(4):273–279.
39. Siru R, Hulse GK, Tait RJ. Assessing motivation to quit smoking in people with mental illness:a review. Addiction. 2009;104(5):719–733.
40. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES):a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507–2520.• Largest tobacco treatment clinical trial conducted to date with a triple-blinded design enrolling 8144 daily smokers, about half of whom had active or past history of psychiatric disorder.
41. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2010;6(6).
42. Banham L, Gilbody S. Smoking cessation in severe mental illness:what works? Addiction. 2010;105(7):1176–1189.
43. Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016;5:Cd006103.
44. Stead LF, Koilpillai P, Fanshawe TR, et al. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Lib. 2016.
45. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence:clinical practice guideline. Rockville (MD):US Department of Health and Human Services; 2000. p. 00–0032.
46. Stead LF, Koilpillai P, Lancaster T. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Lib. 2015.
47. Aubin HJ, Luquiens A, Berlin I. Pharmacotherapy for smoking cessation:pharmacological principles and clinical practice. Br J Clin Pharmacol. 2014;77(2):324–336.
48. Prochaska JJ, Das S, Benowitz NL. Cytisine, the world’s oldest smoking cessation aid. BMJ. 2013;347:f5198.
49. Alsharari SD, Siu EC, Tyndale RF, et al. Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice:effects of methoxsalen, a CYP2A5/6 inhibitor. Nicotine Tob Res. 2014;16(1):18–25.
50. Tejeda HA, Natividad LA, Orfila JE, et al. Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner. Psychopharmacology (Berl). 2012;224(2):289–301.
51. Beard E, Shahab L, Cummings DM, et al. New pharmacological agents to aid smoking cessation and tobacco harm reduction:what has been investigated, and what is in the pipeline? CNS Drugs. 2016;30(10):951–983.
52. Saccone SF, Hinrichs AL, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16(1):36–49.
53. Chen L-S, Baker TB, Jorenby D, et al. Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. Drug Alcohol Depend. 2015;154:278–282.
54. Hughes JR, Gust SW, Skoog K, et al. Symptoms of tobacco withdrawal:a replication and extension. Arch Gen Psychiatry. 1991;48(1):52–59.
55. Hickman NJ, Delucchi KL, Prochaska JJ. Treating tobacco dependence at the intersection of diversity, poverty, and mental illness:a randomized feasibility and replication trial. Nicotine Tob Res. 2015;17(8):1012–1021.
56. Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. Cochrane Lib. 2013.
57. Lindson-Hawley N, Thompson TP, Begh R. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev. 2015;(3):CD006936.
58. Compton MT, Daumit GL, Druss BG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses:a preventive perspective. Harv Rev Psychiatry. 2006;14(4):212–222.
59. Barth J, Jacob T, Daha I, et al. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database Syst Rev. 2015;(7):CD006886.
60. Roberts E, Eden Evins A, McNeill A, et al. Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness:a systematic review and network meta-analysis. Addiction. 2016;111(4):599–612.
61. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2017;3:Cd001292.
62. Hayes SC, Strosahl KD, Wilson KG. Acceptance and commitment therapy:the process and practice of mindful change. New York:Guilford Press. 2011.
63. Lee EB, An W, Levin ME, et al. An initial meta-analysis of acceptance and commitment therapy for treating substance use disorders. Drug Alcohol Depend. 2015;155:1–7.
64. Khoury B, Lecomte T, Fortin G, et al. Mindfulness-based therapy:a comprehensive meta-analysis. Clin Psychol Rev. 2013;33(6):763–771.
65. Cristea IA, Gentili C, Cotet CD, et al. Efficacy of psychotherapies for borderline personality disorder:a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(4):319–328.
66. Kelly MM, Sido H, Forsyth JP, et al. Acceptance and commitment therapy smoking cessation treatment for veterans with posttraumatic stress disorder:a pilot study. J Dual Diagn. 2015;11(1):50–55.
67. Meyers L, Voller EK, McCallum EB, et al. Treating veterans with PTSD and borderline personality symptoms in a 12-week intensive outpatient setting:findings from a pilot program. J Trauma Stress. 2017;30(2):178–181.
68. Shoptaw S, Rotheram‐Fuller E, Yang X, et al. Smoking cessation in methadone maintenance. Addiction. 2002;97(10):1317–1328.
69. Burling TA, Seidner Burling A, Latini D. A controlled smoking cessation trial for substance-dependent inpatients. J Consult Clin Psychol. 2001;69(2):295–304.
70. Rohsenow DJ, Martin RA, Tidey JW, et al. Treating smokers in substance treatment with contingent vouchers, nicotine replacement and brief advice adapted for sobriety settings. J Subst Abuse Treat. 2017;72:72–79.
71. Stead LF, Hartmann‐Boyce J, Perera R, et al. Telephone counselling for smoking cessation. Cochrane Lib. 2013.• Cochrane Review of 77 trials found that proactive telephone counselling aids smokers who seek help from quitlines, that call-back counselling enhances their usefulness, and that there is limited evidence about the optimal number of calls but that there is a likely dose benefit response.
72. Saul J, Davis R, North American Quitline Consortium. Results from the 2012 NAQC Annual Survey of Quitlines [Internet]. Jul 2013. [cited 2017 August]. Available from:https://c.ymcdn.com/sites/www.naquitline.org/resource/resmgr/2012_annual_survey/oct23naqc_2012_final_report_.pdf
73. Zhang L, Malarcher A, Babb S, et al. The impact of a national tobacco education campaign on state-specific quitline calls. Am J Health Promot. 2016;30(5):374–381.
74. Rogers ES, Smelson DA, Gillespie CC, et al. Telephone smoking-cessation counseling for smokers in mental health clinics:a patient-randomized controlled trial. Am J Prev Med. 2016;50(4):518–527.
75. Morris CD, Burns EK, Waxmonsky JA, et al. Smoking cessation behaviors among persons with psychiatric diagnoses:results from a population-level state survey. Drug Alcohol Depend. 2014;136:63–68.• Colorado population survey (n=14,118) found that smoking rates doubled among people with mental health diagnoses and that they were also more likely to attempt quitting, use nicotine replacement therapy more often, and succeed in quitting at similar rates, aside from those with anxiety/PTSD.
76. Borrelli B, Bartlett YK, Tooley E, et al. Prevalence and frequency of mHealth and eHealth use among US and UK smokers and differences by motivation to quit. J Med Internet Res. 2015;17(7):e164.
77. Civljak M, Stead LF, Hartmann‐Boyce J, et al. Internet-based interventions for smoking cessation. Cochrane Lib. 2013.• This Cochrane review summarizing Internet-based interventions used for smoking cessation demonstrates that some of these interventions can be effective at 6 months or longer; however, trials comparing Internet interventions with usual care or self-help did not demonstrate consistent effects.
78. Hunt YM. Self-reported quit rates among users of a national text message based cessation program:early data from the national cancer institute’s smokefreetxt. In Society for Research on Nicotine and Tobacco. Ed.(Eds). Boston (MA); 2013.
79. Spohr SA, Nandy R, Gandhiraj D, et al. Efficacy of SMS text message interventions for smoking cessation:a meta-analysis. J Subst Abuse Treat. 2015;56:1–10.
80. Abroms LC, Boal AL, Simmens SJ, et al. A randomized trial of Text2Quit:a text messaging program for smoking cessation. Am J Prev Med. 2014;47(3):242–250.• Results from this randomized trial demonstrated a biochemically confirmed 11.1% abstinence rate among smokers using Text2Quit (compared to 5% of the control group).
81. Whittaker R, Borland R, Bullen C, et al. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev. 2009;4(4).
82. BinDhim NF, McGeechan K, Trevena L. Who uses smoking cessation apps? A feasibility study across three countries via smartphones. JMIR mHealth uHealth. 2014;2(1):e4.
83. Garrison KA, Pal P, Rojiani R, et al. A randomized controlled trial of smartphone-based mindfulness training for smoking cessation:a study protocol. BMC Psychiatry. 2015;15(1):83.
84. Stoyanov SR, Hides L, Kavanagh DJ, et al. Mobile app rating scale:a new tool for assessing the quality of health mobile apps. JMIR mHealth uHealth. 2015;3(1):e27.
85. Raiff BR, Jarvis BP, Rapoza D. Prevalence of video game use, cigarette smoking, and acceptability of a video game–based smoking cessation intervention among online adults. Nicotine Tob Res. 2012;14(12):1453–1457.
86. Abroms LC, Padmanabhan N, Thaweethai L, et al. iPhone apps for smoking cessation:a content analysis. Am J Prev Med. 2011;40(3):279–285.
87. Krebs P, Burkhalter JE, Snow B, et al. Development and alpha testing of QuitIT:an interactive video game to enhance skills for coping with smoking urges. JMIR Res Protoc. 2013;2(2):e35.• Evaluation of videogame prototype that enables smokers to practice strategies for coping with urges and maintaining abstinence done by experts and former/current smokers demonstrates that this has a strong potential for engaging smokers with suggestions on user interface, pacing, and diversity of the game characters.
88. Ramo DE, Liu H, Prochaska JJ. A mixed-methods study of young adults’ receptivity to using Facebook for smoking cessation:if you build it, will they come? Am J Health Promot. 2015;29(4):e126–e135.
89. Cobb NK, Jacobs MA, Saul J, et al. Diffusion of an evidence-based smoking cessation intervention through Facebook:a randomised controlled trial study protocol. BMJ Open. 2014;4(1):e004089.• Methodology paper for a fractional factorial, randomized control trial of the diffusion of a Facebook application for smoking cessation.
90. Pechmann C, Delucchi K, Lakon CM, et al. Randomised controlled trial evaluation of Tweet2Quit:a social network quit-smoking intervention. Tobacco Control. 2017;26:188–194.
91. Rigotti NA. e-Cigarette use and subsequent tobacco use by adolescents:new evidence about a potential risk of e-cigarettes. JAMA. 2015;314(7):673–674.
92. Dutra LM, Grana R, Glantz SA. Philip Morris research on precursors to the modern e-cigarette since 1990. Tobacco Control.2016. tobaccocontrol-2016-053406.
93. Giovenco DP, Hammond D, Corey CG, et al. E-cigarette market trends in traditional US retail channels, 2012–2013. Nicotine Tob Res. 2014;17(10):1279–1283.
94. Leventhal AM, Strong DR, Kirkpatrick MG, et al. Association of electronic cigarette use with initiation of combustible tobacco product smoking in early adolescence. JAMA. 2015;314(7):700–707.
95. Cummins SE, Zhu S-H, Tedeschi GJ, et al. Use of e-cigarettes by individuals with mental health conditions. Tobacco Control.2014. tobaccocontrol-2013-051511.
96. Prochaska JJ, Grana RA. E-cigarette use among smokers with serious mental illness. PLoS One. 2014;9(11):e113013.
97. Hess I, Lachireddy K, Capon A. A systematic review of the health risks from passive exposure to electronic cigarette vapour. Public Health Res Pract. 2016;26(2):e2621617.
98. Kasza KA, Ambrose BK, Conway KP, et al. Tobacco-Product Use by Adults and Youths in the United States in 2013 and 2014. New England Journal of Medicine. 2017;376:342–353.
99. Goniewicz ML, Gupta R, Lee YH, et al. Nicotine levels in electronic cigarette refill solutions:a comparative analysis of products from the US, Korea, and Poland. Int J Drug Policy. 2015;26(6):583–588.
100. Hartmann-Boyce J, McRobbie H, Bullen C, et al. Electronic cigarettes for smoking cessation. Cochrane Lib. 2016.
101. Bhatnagar A, Whitsel LP, Ribisl KM, et al. Electronic cigarettes. Circulation. 2014;130(16):1418–1436.
102. Benowitz NL, Henningfield JE., Establishing a Nicotine Threshold for Addiction–The Implications for Tobacco Regulation. New England Journal of Medicine. 1994;331(2):123–125.
103. Tidey JW, Pacek LR, Koopmeiners JS, et al. Effects of 6-week use of reduced-nicotine content cigarettes in smokers with and without elevated depressive symptoms. Nicotine Tob Res. 2017;19(1):59-67.
104. Hammond D, O’Connor RJ. Reduced nicotine cigarettes:smoking behavior and biomarkers of exposure among smokers not intending to quit. Cancer Epidemiol Prev Biomarkers. 2014;23(10):2032–2040.
105. Mercincavage M, Souprountchouk V, Tang KZ, et al. A randomized controlled trial of progressively reduced nicotine content cigarettes on smoking behaviors, biomarkers of exposure, and subjective ratings. Cancer Epidemiol Prev Biomarkers. 2016;25(7):1125–1133.
106. Allen SI, Foulds J, Pachas GN, et al. A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders:trial design and protocol. BMC Public Health. 2017;17(1):100.
107. Donny EC, Hatsukami DK. Randomized trial of reduced-nicotine standards for cigarettes. N Engl J Med. 2016;374(4):396–397.
108. Hatsukami DK, Kotlyar M, Hertsgaard LA, et al. Reduced nicotine content cigarettes:effects on toxicant exposure, dependence and cessation. Addiction. 2010;105(2):343–355.
109. Auer R, Concha-Lozano N, Jacot-Sadowski I, et al. Heat-not-burn tobacco cigarettes:smoke by any other name. JAMA Intern Med. 2017;177:1050.
110. Farsalinos KE, Yannovits N, Sarri T, et al. Nicotine delivery to the aerosol of a heat-not-burn tobacco product:comparison with a tobacco cigarette and e-cigarettes. Nicotine Tob Res. 2017.
111. Available from:http://www.healthypeople.gov/
112. Prochaska JJ, Fromont SC, Leek D, et al. Evaluation of an evidence-based tobacco treatment curriculum for psychiatry residency training programs. Acad Psychiatry. 2008;32(6):484–492.
113. Metse AP, Wiggers JH, Wye PM, et al. Smoking and mental illness:a bibliometric analysis of research output over time. Nicotine Tob Res. 2017;19(1):24–31.
114. Lembke A, Humphreys K. A call to include people with mental illness and substance use disorders alongside ‘regular’ smokers in smoking cessation research. Tob Control. 2016;25(3):261–262.